Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 1888-1895

  Goldman, John M ^a   Majhail, Navneet S ^a   Klein, John P ^a   Wang, Zhiwei ^a   Sobocinski, Kathleen A ^a   Arora, Mukta ^a   Horowitz, Mary M ^a   Rizzo, J Douglas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CHILD; CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; ADOLESCENT; ALLOTRANSPLANTATION; CANCER STAGING; COHORT ANALYSIS; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; PATHOLOGY; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ADULT; CHILD; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951632041     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.7757     Document Type: Article

References (19)

1. Giralt SA, Arora M, Goldman JM, et al: Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 137:461-467, 2007 (Pubitemid 46698285)
2. Lee SJ, Kukreja M, Wang T, et al: Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 112:3500-3507, 2008
3. Gale RP, Hehlmann R, Zhang MJ, et al: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood 91:1810-1819, 1998
4. Goldman JM: How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828-2837, 2007
5. Arora M, Weisdorf DJ, Spellman SR, et al: HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol 27:1644-1652, 2009
6. Copelan EA, Crilley PA, Szer J, et al: Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 15:851-855, 2009
7. Socié G, Stone JV, Wingard JR, et al: Longterm survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 341:14-21, 1999
8. Robin M, Guardiola P, Devergie A, et al: A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 19:1613-1620, 2005 (Pubitemid 43090406)
9. Pasquini M, Wang Z: Current uses and outcomes of hematopoietic stem cell transplantation 2009: Summary slides Part I. CIBMTR Newsletter 15:7-11, 2009 http://www.cibmtr.org/ReferenceCenter/Newsletters/index.html
10. Farag SS, Bacigalupo A, Eapen M, et al: The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 12:876-884, 2006 (Pubitemid 44070674)
11. Clark TG, Altman DG, De Stavola BL: Quantification of the completeness of follow-up. Lancet 359:1309-1310, 2002 (Pubitemid 34310638)
12. Lee SJ, Klein JP, Barrett AJ, et al: Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse. Blood 100:406-414, 2002 (Pubitemid 34761100)
13. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
14. Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data (ed 2). New York, New York, Springer-Verlag, 2003
15. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
16. Andersen PK, Vaeth M: Simple parametric and nonparametric models for excess and relative mortality. Biometrics 45:523-535, 1989
17. Ramlou-Hansen H: Smoothing counting process intensities by means of kernel functions. Ann Statist 11:453-466, 1983
18. Bhatia S, Francisco L, Carter A, et al: Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study. Blood 110:3784-3792, 2007 (Pubitemid 350159650)
19. Rizzo JD, Wingard JR, Tichelli A, et al: Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: Joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 12:138-151, 2006 (Pubitemid 43138009)